AN ACUTE MYELOCYTER LEUKEMIA CASE AFTER TREATMENT FOR SMALL CELL LUNG CANCER

It is known that the incidence of secondary malignancy is increased in patients treated with cytotoxic drugs and radiotherapy. Among cytotoxic drugs especially alkylating agents are responsible. Chemotherapy induced acute non-lymphoblastic leukamia (ANLL) develops approximately 4-5 years later. ANLL was diagnosed in our 36 years old male patient with oat cell lung cancer who had been treated with VAC (vincristine, doxorubicine, cyclophosphamide) and EP (Etoposide, Cisplatin) alternating chemotherapy schedule. The diagnosis of M2 acute myeloblastic leukemia (AML) was established 8 months after his first chemotherapy course of oat cell lung cancer. He treated with Idarubicine 12 mg/m2 (1-3. days) and Cytosine Arabinocide 100 mg/m2 (1-7. days). However, he died because of multisystem failure resulting from neutropenic sepsis on 22th day of chemotherapy course. Alkylating agents are responsible for the development of leukemia; however genetic predisposition and primary disease are also contributing factors.